A Phase I Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma
Latest Information Update: 22 Jan 2025
At a glance
- Drugs Ipilimumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms NEO-GLITIPNI
- 20 Jan 2025 Status changed from not yet recruiting to recruiting.
- 26 Oct 2023 New trial record